232 related articles for article (PubMed ID: 8797588)
1. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979.
Dantzig AH; Shepard RL; Cao J; Law KL; Ehlhardt WJ; Baughman TM; Bumol TF; Starling JJ
Cancer Res; 1996 Sep; 56(18):4171-9. PubMed ID: 8797588
[TBL] [Abstract][Full Text] [Related]
2. RS-33295-198: a novel, potent modulator of P-glycoprotein-mediated multidrug resistance.
Slate DL; Bruno NA; Casey SM; Zutshi N; Garvin LJ; Wu H; Pfister JR
Anticancer Res; 1995; 15(3):811-4. PubMed ID: 7645963
[TBL] [Abstract][Full Text] [Related]
3. Potent reversal of multidrug resistance by ningalins and its use in drug combinations against human colon carcinoma xenograft in nude mice.
Chou TC; Guan Y; Soenen DR; Danishefsky SJ; Boger DL
Cancer Chemother Pharmacol; 2005 Oct; 56(4):379-90. PubMed ID: 15875185
[TBL] [Abstract][Full Text] [Related]
4. Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities.
Dantzig AH; Shepard RL; Law KL; Tabas L; Pratt S; Gillespie JS; Binkley SN; Kuhfeld MT; Starling JJ; Wrighton SA
J Pharmacol Exp Ther; 1999 Aug; 290(2):854-62. PubMed ID: 10411602
[TBL] [Abstract][Full Text] [Related]
5. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance.
Newman MJ; Rodarte JC; Benbatoul KD; Romano SJ; Zhang C; Krane S; Moran EJ; Uyeda RT; Dixon R; Guns ES; Mayer LD
Cancer Res; 2000 Jun; 60(11):2964-72. PubMed ID: 10850444
[TBL] [Abstract][Full Text] [Related]
6. Reversal of multidrug resistance by the P-glycoprotein modulator, LY335979, from the bench to the clinic.
Dantzig AH; Law KL; Cao J; Starling JJ
Curr Med Chem; 2001 Jan; 8(1):39-50. PubMed ID: 11172691
[TBL] [Abstract][Full Text] [Related]
7. Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine.
Jin J; Wang FP; Wei H; Liu G
Cancer Chemother Pharmacol; 2005 Feb; 55(2):179-88. PubMed ID: 15378274
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.
Mistry P; Stewart AJ; Dangerfield W; Okiji S; Liddle C; Bootle D; Plumb JA; Templeton D; Charlton P
Cancer Res; 2001 Jan; 61(2):749-58. PubMed ID: 11212278
[TBL] [Abstract][Full Text] [Related]
9. Differential interactions of Pgp inhibitor thaliblastine with adriamycin, etoposide, taxol and anthrapyrazole CI941 in sensitive and multidrug-resistant human MCF-7 breast cancer cells.
Chen G; Teicher BA; Frei E
Anticancer Res; 1996; 16(6B):3499-505. PubMed ID: 9042212
[TBL] [Abstract][Full Text] [Related]
10. Cytogenetic and molecular characterization of tumors in nude mice derived from a multidrug-resistant human leukemia cell line.
Hill AB; Beck WT; Trent JM
Cancer Res; 1988 Jan; 48(2):393-8. PubMed ID: 2891436
[TBL] [Abstract][Full Text] [Related]
11. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
[TBL] [Abstract][Full Text] [Related]
12. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
[TBL] [Abstract][Full Text] [Related]
13. Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance.
Fu L; Liang Y; Deng L; Ding Y; Chen L; Ye Y; Yang X; Pan Q
Cancer Chemother Pharmacol; 2004 Apr; 53(4):349-56. PubMed ID: 14666379
[TBL] [Abstract][Full Text] [Related]
14. Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979.
Shepard RL; Cao J; Starling JJ; Dantzig AH
Int J Cancer; 2003 Jan; 103(1):121-5. PubMed ID: 12455064
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of dihydropyrroloquinolines that selectively antagonize P-glycoprotein.
Lee BD; Li Z; French KJ; Zhuang Y; Xia Z; Smith CD
J Med Chem; 2004 Mar; 47(6):1413-22. PubMed ID: 14998330
[TBL] [Abstract][Full Text] [Related]
16. Reversal of P-glycoprotein associated multidrug resistance by new isoprenoid derivatives.
Hayashi M; Koike K; Rho MC; Kuwano M; Kishiye T; Komiyama K
Anticancer Drug Des; 2001; 16(4-5):255-60. PubMed ID: 12049484
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells.
Beck WT; Cirtain MC; Danks MK; Felsted RL; Safa AR; Wolverton JS; Suttle DP; Trent JM
Cancer Res; 1987 Oct; 47(20):5455-60. PubMed ID: 2888532
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel.
Zhu X; Sui M; Fan W
Anticancer Res; 2005; 25(3B):1953-62. PubMed ID: 16158930
[TBL] [Abstract][Full Text] [Related]
19. Effects of mitomycin C and carboplatin pretreatment on multidrug resistance-associated P-glycoprotein expression and on subsequent suppression of tumor growth by doxorubicin and paclitaxel in human metastatic breast cancer xenografted nude mice.
Ihnat MA; Nervi AM; Anthony SP; Kaltreider RC; Warren AJ; Pesce CA; Davis SA; Lariviere JP; Hamilton JW
Oncol Res; 1999; 11(7):303-10. PubMed ID: 10757444
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative.
Hyafil F; Vergely C; Du Vignaud P; Grand-Perret T
Cancer Res; 1993 Oct; 53(19):4595-602. PubMed ID: 8402633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]